Albert Labs Files US Provisional Patent Application and Proves Out Consistent and Rapidly Scalable Production of Psilocybe and Other Mycelia Post published:March 30, 2022 Post category:Press Release
Albert Labs (CSE:ABRT) Closes $4.7m Private Placement; Begins Trading on the Canadian Securities Exchange Post published:March 10, 2022 Post category:Press Release
MHRA Guidance on the use of Real-World Data in Clinical Studies for Regulatory Decision-Making Supports Albert Labs’ Licensing Pathway Post published:January 4, 2022 Post category:Press Release
Albert Labs (CSE: ABRT) Receive Conditional Approval for CSE Listing & Appoint Chrystal Capital Partners to Advise on European Listing Post published:November 29, 2021 Post category:Press Release
Albert Labs Announces a Distinguished Clinical and Scientific Advisory Board Post published:June 24, 2021 Post category:Press Release
MEC Announces Submission of Listing Statement to the CSE in Coordination with Albert Labs RTO Post published:June 3, 2021 Post category:Press Release
Adding to their Expert Team, Albert Labs Announces the Formation and Chairs of its Two Advisory Boards Post published:May 25, 2021 Post category:Press Release
MEC Signs RTO Definitive Agreement To Acquire Albert Labs, A European Psychedelic Drug Researcher & Developer Post published:March 5, 2021 Post category:Press Release
MEC announces letter of intent to acquire Albert Labs, a European psychedelic drug researcher & developer Post published:January 5, 2021 Post category:Press Release